Pardes Biosciences is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for gastrointestinal and liver diseases. The company leverages its proprietary drug discovery platform to target the microbiome and other pathways involved in disease pathogenesis.

Foresite Capital is a multi-stage healthcare and life sciences investment firm with ~ $3.5B in assets under management (as of 12/31/23). The firm aims to address areas of great unmet need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Foresite Capital uses a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare, including 10x Genomics, Relay Therapeutics, Element Biosciences, Inscripta, as well as companies developing next generation therapeutics. Founded in 2011, Foresite Capital is based in San Francisco. 

Intellia Therapeutics

Jounce Therapeutics

SAGE Therapeutics

Solid Biosciences

SomaLogic

Vaxcyte

Twist Bioscience

10X Genomics

23andMe

Invivyd

Adaptimmune

Alector

Fulcrum Therapeutics

Verona Pharma

Arcus Biosciences

Orchard Therapeutics

Pardes Biosciences

Protagonist Therapeutics

Quantum SI

REGENXBIO

Relay Therapeutics

Replimune Group

Foresite Capital

We're happy to see our colleague Shoman Kasbekar included in this piece in the Biomarker newsletter covering rising stars in biotech investing and creation, how they got started, and lessons learned. Shoman shares his perspective on how the success of the investment only begins with the investment itself. Read more at the link below. 

Our managing director Vik Bajaj sat down with Maneesh Jain at portfolio company Mirvie for a conversation on the maternal health crisis, and why precision medicine represents the future of pregnancy health. Mirvie aims to predict pregnancy complications before they happen by using RNA messages to reveal the underlying biology of pregnancy health. We welcome your comments on this important conversation!

#maternalhealth #pregnancy #precisionmedicine

Our head of research, Scott McIsaac, sat down with former Foresite Labs Fellow and current associate Chase Kelley recently to discuss his experiences participating in the joint Foresite Capital & Foresite Labs Fellows program. Check it out at the link below. We are now accepting applications for our next cohort: https://lnkd.in/gJuaCbPR

#lifesciences #fellowships #healthcare #foresitelabs

COM:FORESITECAPITAL

Pardes Biosciences

Analysis Not Available